IDEAYA Biosciences, Inc.
IDYA evidence brief
What we can confirm
- BioSniper Score:
- 8.2 / 10
- Market Cap:
- $3.75B
- Lead Asset:
- Darovasertib (Phase 3)
What it means
What to watch
Prepared research question
What matters most for IDYA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IDYA
IDEAYA Biosciences is a precision oncology company developing a pipeline of first-in-class small molecule and ADC programs, with its most advanced asset, darovasertib, in Phase 3 for uveal melanoma and a cash position of $272.6M as of 2026-06-30 [sec].
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 13 clinical trials for IDEAYA Biosciences, Inc..
IDEAYA Biosciences is a precision oncology company developing a pipeline of first-in-class small molecule and ADC programs, with its most advanced asset, darovasertib, in Phase 3 for uveal melanoma and a cash position of $272.6M as of 2026-06-30 [sec].
- Cash and equivalents of $272.6M as of 2026-06-30 [sec].
- Total revenue of $8.9M and net loss of -$112.5M for the period ending 2026-06-30 [sec].
- Lead program darovasertib (PKC inhibitor) is in Phase 3 for uveal melanoma [sec_mda · as of 2026-05-05].
- Pipeline includes nine first-in-class candidates across four focus areas: darovasertib, ADC/DDR combinations, MTAP pathway, and next-generation therapies [sec_mda · as of 2026-02-17].
- Selected IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, as a development candidate [sec · filed 2025-04-30].
What works
- Strong cash position of $272.6M as of 2026-06-30 provides extended runway for operations [sec].
- Multiple first-in-class programs in clinical development, including darovasertib in Phase 3 and IDE892 in IND-enabling studies [sec_mda · as of 2026-05-05][sec · filed 2025-04-30].
- Strategic collaborations with leading pharmaceutical companies support clinical development [sec_mda · as of 2026-02-17].
What to weigh
- Net loss of -$112.5M for the period ending 2026-06-30 reflects ongoing R&D investment without approved product revenue [sec].
- Total revenue of only $8.9M as of 2026-06-30 indicates minimal commercial sales [sec].
- Dependence on clinical trial outcomes for multiple early-stage programs introduces significant regulatory and technical risk [sec_mda · as of 2026-05-05].
From the filings
Quoted directly from source documents.
Darovasertib is the most advanced program
“Darovasertib is an oral, potent and selective small molecule inhibitor of protein kinase C and our most advanced clinical program.”
SEC MD&A · May 5, 2026
Pipeline includes nine first-in-class candidates
“Our current clinical pipeline consists of nine potential first-in-class product candidates across four clinical focus areas”
SEC MD&A · February 17, 2026
IDE892 selected as development candidate
“Selected IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, as a development candidate.”
SEC filings · April 30, 2025
Catalyst timeline
- 2019-06-28 · Phase 2 Start for darovasertib in uveal melanoma — Initial Phase 2 study of IDE196 (darovasertib) in GNAQ/11 or PRKC fusion tumors.
- 2021-04-14 · Phase 1 Start for IDE397 (MAT2A inhibitor) — First-in-human study of IDE397 in advanced solid tumors.
- 2023-04-18 · Phase 1 Start for IDE161 (PARG inhibitor) — Study of PARG inhibitor IDE161 in advanced solid tumors.
- 2023-07-03 · Phase 2 Start for (neo)adjuvant darovasertib — Neoadjuvant/adjuvant study of darovasertib in localized ocular melanoma.
- 2023-10-31 · Phase 3 Start for darovasertib + crizotinib — Phase 3 trial of darovasertib plus crizotinib versus investigator's choice in HLA-A2 negative metastatic uveal melanoma.
Risks & what to watch (3)›
Key risks
- No approved products — Company has no approved products; all revenue is from collaborations/grants, not product sales [sec].
- Clinical trial risk — Multiple early-stage programs depend on successful clinical outcomes; failure of any could materially impact pipeline [sec_mda · as of 2026-05-05].
- Net loss trend — Net loss of -$112.5M as of 2026-06-30 indicates ongoing cash burn without near-term product revenue [sec].
What to watch
- Phase 3 darovasertib trial for uveal melanoma; data readouts could be pivotal for approval [sec_mda · as of 2026-05-05].
- Initiation of Phase 1 dose escalation for IDE574 (KAT6/7) in Q1 2026 [sec · filed 2026-01-12].
- IND submission for CDKN2A program by end of 2026 [sec · filed 2026-01-12].
- Progress of IDE892 (PRMT5 inhibitor) into clinical development [sec · filed 2025-04-30].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated September 29, 2026 · How we verify sources →
Run IDEAYA Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IDEAYA Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 2/Phase 3
7 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 14.2%
- Days to cover
- 6.3
- Shares short
- 10,564,351
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IDYA short interestGovernance
Frequently asked questions
What is the AI investment thesis for IDEAYA Biosciences, Inc.?
IDEAYA Biosciences is a precision oncology company developing a pipeline of first-in-class small molecule and ADC programs, with its most advanced asset, darovasertib, in Phase 3 for uveal melanoma and a cash position of $272.6M as of 2026-06-30 [sec].
What is IDEAYA Biosciences, Inc.'s lead drug candidate?
IDEAYA Biosciences, Inc.'s most advanced tracked candidate is Darovasertib (Phase 3) for Uveal Melanoma.
Who is the CEO of IDEAYA Biosciences, Inc.?
Mr. Yujiro S. Hata is the chief executive officer of IDEAYA Biosciences, Inc. (IDYA).
Where is IDEAYA Biosciences, Inc. headquartered?
IDEAYA Biosciences, Inc. (IDYA) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does IDEAYA Biosciences, Inc. focus on?
IDEAYA Biosciences, Inc. develops therapies across Oncology, Neurology, Ophthalmology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.